PDF(Sci-hub)
Abstract：
BACKGROUND: In this retrospective surveillance, epidemiology, and end results (SEER) registry analysis, we investigated the role of chemotherapy (CT) in the treatment of olfactory neuroblastoma (ON), an exceedingly rare sino-nasal tumor typically treated with surgery and/or radiation therapy (RT).
METHODS: We analyzed all patients in the SEER registry diagnosed with a single primary malignancy of ON, a primary tumor site within the nasal cavity or surrounding sinuses, sufficient staging information to derive Kadish staging, and >0 days of survival, ensuring follow-up data. Receipt of CT in the SEER registry was documented as either Yes or No/Unknown.
RESULTS: Six hundred and thirty-six patients were identified. One hundred and ninety-five patients received CT as part of their treatment for ON. Following propensity score matching and inverse probability of treatment weighting, there was inferior overall survival (OS) (HR 1.7, 95% CI: 1.3-2.2, P = .001) and cancer-specific survival (CSS) (HR 1.8, 95% CI: 1.3-2.4, P < .001) for patients who received CT compared to those who were not treated with CT or had unknown CT status. On subgroup analysis, the only patient population that derived benefit from CT were patients who did not receive surgery and were treated with CT and/or RT (HR 0.3, 95% CI: 0.14-0.61, P < .001).
CONCLUSIONS: Based on this retrospective SEER registry analysis, the use of CT in the management of ON is associated with decreased OS. Our analysis suggests that patients who are considered nonsurgical candidates may benefit from the addition of CT.
METHODS: We analyzed all patients in the SEER registry diagnosed with a single primary malignancy of ON, a primary tumor site within the nasal cavity or surrounding sinuses, sufficient staging information to derive Kadish staging, and >0 days of survival, ensuring follow-up data. Receipt of CT in the SEER registry was documented as either Yes or No/Unknown.
RESULTS: Six hundred and thirty-six patients were identified. One hundred and ninety-five patients received CT as part of their treatment for ON. Following propensity score matching and inverse probability of treatment weighting, there was inferior overall survival (OS) (HR 1.7, 95% CI: 1.3-2.2, P = .001) and cancer-specific survival (CSS) (HR 1.8, 95% CI: 1.3-2.4, P < .001) for patients who received CT compared to those who were not treated with CT or had unknown CT status. On subgroup analysis, the only patient population that derived benefit from CT were patients who did not receive surgery and were treated with CT and/or RT (HR 0.3, 95% CI: 0.14-0.61, P < .001).
CONCLUSIONS: Based on this retrospective SEER registry analysis, the use of CT in the management of ON is associated with decreased OS. Our analysis suggests that patients who are considered nonsurgical candidates may benefit from the addition of CT.
摘要：
背景：在这次回顾性监测中，流行病学,和最终结果(SEER)注册表分析，我们研究了化疗（CT）在嗅觉神经母细胞瘤（ON）治疗中的作用，一种极其罕见的鼻部肿瘤，通常采用手术和/或放射治疗（RT）治疗。
方法：我们分析了SEER注册中诊断为单一原发性恶性肿瘤的所有患者，鼻腔或周围鼻窦内的原发肿瘤部位，足够的分期信息来推导Kadish分期，存活>0天，确保后续数据。SEER注册表中的CT接收记录为“是”或“否/未知”。
结果：确认了6136名患者。作为ON治疗的一部分，有119名患者接受了CT治疗。在倾向评分匹配和治疗加权的逆概率之后，与未接受CT治疗或CT状态未知的患者相比,接受CT治疗的患者的总生存期(OS)(HR1.7,95%CI:1.3~2.2,P=.001)和癌症特异性生存期(CSS)(HR1.8,95%CI:1.3~2.4,P<.001)较差.关于子群分析，唯一从CT获益的患者人群是未接受手术并接受CT和/或RT治疗的患者(HR0.3,95%CI:0.14~0.61,P<.001).
结论：基于此回顾性SEER注册分析，在ON管理中使用CT与降低OS相关。我们的分析表明，被认为是非手术候选人的患者可能会从CT的增加中受益。
方法：我们分析了SEER注册中诊断为单一原发性恶性肿瘤的所有患者，鼻腔或周围鼻窦内的原发肿瘤部位，足够的分期信息来推导Kadish分期，存活>0天，确保后续数据。SEER注册表中的CT接收记录为“是”或“否/未知”。
结果：确认了6136名患者。作为ON治疗的一部分，有119名患者接受了CT治疗。在倾向评分匹配和治疗加权的逆概率之后，与未接受CT治疗或CT状态未知的患者相比,接受CT治疗的患者的总生存期(OS)(HR1.7,95%CI:1.3~2.2,P=.001)和癌症特异性生存期(CSS)(HR1.8,95%CI:1.3~2.4,P<.001)较差.关于子群分析，唯一从CT获益的患者人群是未接受手术并接受CT和/或RT治疗的患者(HR0.3,95%CI:0.14~0.61,P<.001).
结论：基于此回顾性SEER注册分析，在ON管理中使用CT与降低OS相关。我们的分析表明，被认为是非手术候选人的患者可能会从CT的增加中受益。
